Citations

Showing 10 of 108081 citations.

Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials
Brosnahan, Godela , Rahbari-Oskoui, Frederic F. , Patterson, Charity G. , Bae, Kyongtae T. , Schrier, Robert W., Braun, William E. , Chapman, Arlene B., Flessner, Michael F., Harris, Peter C. , Steinman, Theodore I., Torres, Vicente E. , Abebe, Kaleab Z , Perrone, Ronald D. , Harris, Peter C , Torres, Vicente E , Rahbari-Oskoui, Frederic F

Mayo Clinic

Current Hypertension Reviews | May 2, 2017 | Volume: 13 | Issue: 2 | Pages: No page available

10.2174/1573402113666170427142815 | PMID 28460625 Get It

Risk Factors and Time to Recurrent Ipsilateral and Contralateral Patellar Dislocations
Christensen, Tyson C. , Sanders, Thomas L. , Pareek, Ayoosh , Mohan, Rohith , Dahm, Diane L., Krych, Aaron J. , Krych, Aaron J

Mayo Clinic

The American Journal of Sports Medicine | May 2, 2017 | Volume: 45 | Issue: 9 | Pages: 2105-2110

10.1177/0363546517704178 | PMID 28463535 Get It

Background: Previous studies have reported variable rates of recurrent lateral patellar instability mainly because of limited cohort sizes. In addition, there is currently a lack of information on contralateral patellar instability. Purpose: To evaluate the rate of recurrent ipsilateral patellar dislocations and contralateral patellar dislocations after a first-time lateral patellar dislocation. Additionally, risk factors associated with recurrent dislocations (ipsilateral or contralateral) and time to recurrence were investigated. Study Design: Cohort study; Level of evidence, 3. Methods: This population-based study included 584 patients with a first-time lateral patellar dislocation occurring between 1990 and 2010. A retrospective review was conducted to gather information about the injury, subsequent dislocations (ipsilateral or contralateral), and structural characteristics including trochlear dysplasia, patella alta, and tibial tubercle to trochlear groove (TT-TG) distance. Risk factors were assessed to delineate associations with subsequent dislocations and time to recurrence. Results: At a mean follow-up of 12.4 years, 173 patients had ipsilateral recurrence, and 25 patients had a subsequent contralateral dislocation. At 20 years, the cumulative incidence of ipsilateral recurrence was 36.0%, while the cumulative incidence of contralateral dislocations was 5.4%. Trochlear dysplasia (odds ratio [OR], 18.1), patella alta (OR, 10.4), age <18 years at the time of the first dislocation (OR, 2.4), elevated TT-TG distance (OR, 2.1), and female sex (OR, 1.5) were associated with recurrent ipsilateral dislocations. Time to recurrence was significantly decreased in patients with trochlear dysplasia (23.0 months earlier time to recurrence; P < .001), elevated TT-TG distance (18.5 months; P < .001), patella alta (16.4 months; P = .001), and age <18 years at the time of the first dislocation (15.4 months; P < .001). Risk factors for subsequent contralateral dislocations included patella alta and trochlear dysplasia. Conclusion: At 20 years after a first-time lateral patellar dislocation, the cumulative incidence of recurrent ipsilateral patellar dislocations was 36.0%, compared with 5.4% for contralateral dislocations. Trochlear dysplasia, elevated TT-TG distance, patella alta, age <18 years at the time of the first dislocation, and female sex were associated with ipsilateral recurrence. Trochlear dysplasia, elevated TT-TG distance, patella alta, and age <18 years at the time of the first dislocation were predictive of a statistically significant decrease in time to recurrence.
Biopsy of CT-Occult Bone Lesions Using Anatomic Landmarks for CT Guidance
Hillen, Travis J. , Talbert, Robert J., Friedman, Michael , Long, Jeremiah R. , Jennings, Jack W. , Wessell, Daniel E. , Baker, Jonathan C.

Mayo Clinic

American Journal of Roentgenology | May 2, 2017 | Volume: 209 | Issue: 1 | Pages: 214-221

10.2214/ajr.16.17468 | PMID 28463540 Get It

Septic Arthritis in Emergency Departments in the US : A National Study of Health Care Utilization and Time Trends
Singh, Jasvinder A. , Yu, Shaohua , Singh, Jasvinder A

Mayo Clinic

Arthritis Care & Research | May 2, 2017 | Volume: 70 | Issue: 2 | Pages: 320-326

10.1002/acr.23270 | PMID 28464432 Get It

Objective To assess the health care utilization and emergency department ( ED ) charges for septic arthritis. Methods We performed a retrospective cohort study of ED visits with septic arthritis as the primary diagnosis using the US Nationwide Emergency Department Sample data from 2009–2012. We examined ED charges, hospitalization, and associated time trends. Multivariable models were adjusted for demographics (age, sex, insurance status, residence, and household income), comorbidity, and hospital characteristics to assess factors associated with ED charges and hospitalization. Results Septic arthritis was responsible for 16,382 ED visits in 2012 in the US , which constituted 0.01% of all ED visits. The number of ED visits was stable from 2009–2012. Total ED charges were $34.6, $30.6, and $36.9 million in 2009, 2010, and 2012, respectively, and mean ED charges were $2,149, $1,866, and $2,257, respectively. The majority of the patients with an ED visit for septic arthritis were hospitalized: 82%, 83%, and 84% in 2009, 2010, and 2012, respectively. Metropolitan residence and western US location were associated with higher ED charges, and the highest income quartile, renal failure, or osteoarthritis were associated with lower ED charges. Female sex, metropolitan residence, metropolitan teaching hospital status, and medical comorbidity (diabetes mellitus, hyperlipidemia, hypertension, chronic obstructive pulmonary disease, coronary heart disease, gout, osteoarthritis, renal failure, and heart failure) were associated with a higher risk of hospitalization. Conclusion Comorbidities were associated with a higher risk of hospitalization after an ED visit for septic arthritis, but not higher ED charges. No time trends in ED visit incidence, ED charges, or hospitalization rate for septic arthritis from 2009–2012 were noted.
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor–positive breast cancer: NCIC CTG MA.27
Lipton, Allan, Chapman, Judith‐Anne W. , Leitzel, Kim, Garg, Ashwani, Budd, G. Thomas, Rabaglio, Manuela , Han, Lei , Elliott, Catherine, Shepherd, Lois E. , Goss, Paul E. , Ali, Suhail M., Ingle, James N. , Pritchard, Kathleen I. , Ellis, Matthew J. , Sledge, George W. , Rabaglio-Poretti, Manuela

Mayo Clinic

Cancer | May 2, 2017 | Volume: 123 | Issue: 13 | Pages: 2444-2451

10.1002/cncr.30682 | PMID 28464211 Get It

BACKGROUNDBreast cancer patients in the MA.27 trial had similar outcomes with steroidal aromatase inhibitor (AI) exemestane and nonsteroidal anastrozole. AIs increase the risk of osteoporosis. This study examined the effects of self‐reported osteoporosis and osteoporosis therapy (OPT) on outcomes.METHODSThe MA.27 phase 3 adjuvant trial enrolled 7576 postmenopausal women. The primary outcome was event‐free survival (EFS), and the secondary outcome was distant disease–free survival (DDFS). Patients were permitted bisphosphonates to prevent or treat osteopenia/osteoporosis. In a multivariate, stratified Cox regression, factors were significant with a 2‐sided Wald test P value ≤ .05.RESULTSOsteoporosis was reported at the baseline by 654 of the 7576 women (8.6%) and in total by 1294 patients. Oral OPT was received at the baseline by 815 of the 7576 women (10.8%) and in total by 2711 patients (36%). With a median follow‐up of 4.1 years, 693 EFS events (9.15%) and 321 DDFS events (4.2%) occurred. Osteoporosis was not associated with EFS or DDFS. Few EFS events occurred before the initiation of OPT, with no substantive evidence of a time‐differing effect on outcomes (nonproportional hazards). OPT (yes vs no) was significantly associated with improved EFS (hazard ratio [HR] for yes vs no, 0.67; 95% confidence interval [CI], 0.57‐0.80; P < .001) and DDFS (HR, 0.57; 95% CI, 0.44‐0.73; P <. 001). Time‐differing (time‐dependent) OPT was not (EFS; P = .45). OPT did not alter the incidence of visceral‐only metastasis (P = .31).CONCLUSIONSOral OPT, administered to postmenopausal breast cancer patients receiving adjuvant AI therapy, was associated with improved EFS and DDFS; the time of OPT initiation (a time‐dependent effect) did not affect the outcome. OPT did not alter the risk of visceral metastasis. Cancer 2017;123:2444–51. © 2017 American Cancer Society.
Association between Alcohol Consumption, Folate Intake, and Risk of Pancreatic Cancer: A Case-Control Study
Yallew, Winta, Bamlet, William R. , Oberg, Ann L. , Anderson, Kristin E. , Olson, Janet E., Petersen, Gloria M. , Jansen, Rick J. , Olson, Janet E. , Sinha, Rashmi R. , Stolzenberg‐Solomon, Rachael Z. , Bamlet, William R , Jansen, Rick J

Mayo Clinic

Nutrients | May 2, 2017 | Volume: 9 | Issue: 5 | Pages: 448

10.3390/nu9050448 | PMID 28468303 Get It

Pancreatic cancer is one of the most fatal common cancers affecting both men and women, representing about 3% of all new cancer cases in the United States. In this study, we aimed to investigate the association of pancreatic cancer risk with alcohol consumption as well as folate intake. We performed a case-control study of 384 patients diagnosed with pancreatic cancer from May 2004 to December 2009 and 983 primary care healthy controls in a largely white population (>96%). Our findings showed no significant association between risk of pancreatic cancer and either overall alcohol consumption or type of alcohol consumed (drinks/day). Our study showed dietary folate intake had a modest effect size, but was significantly inversely associated with pancreatic cancer (odds ratio (OR) = 0.99, p < 0.0001). The current study supports the hypothesis that pancreatic cancer risk is reduced with higher food-based folate intake.
Potential role of high-stress employment in hypertension
Buenz, Eric J. , Bauer, Brent A.

Mayo Clinic

JRSM Open | May 2, 2017 | Volume: 8 | Issue: 5 | Pages: No page available

10.1177/2054270417694292 | PMID 28515952 Get It

We report a patient with a reduction in blood pressure through cessation of high-stress employment.
Carotid revascularization and medical management for asymptomatic carotid stenosis: Protocol of the CREST-2 clinical trials
Howard, Virginia J. , Lal, Brajesh K. , Turan, Tanya N. , Roubin, Gary S., Brown, Robert D. , Voeks, Jenifer H. , Barrett, Kevin M. , Lazar, Ronald M. , Moore, Wesley S. , Wadley, Virginia G. , Moy, Claudia S., Chimowitz, Marc I. , Howard, George , Brott, Thomas G. , Meschia, James F. , Demaerschalk, Bart M. , Huston, John , Chaturvedi, Seemant , Howard, Virginia J , Howard, George

Mayo Clinic

International Journal of Stroke | May 2, 2017 | Volume: 12 | Issue: 7 | Pages: 770-778

10.1177/1747493017706238 | PMID 28462683 Get It

Rationale Trials conducted decades ago demonstrated that carotid endarterectomy by skilled surgeons reduced stroke risk in asymptomatic patients. Developments in carotid stenting and improvements in medical prevention of stroke caused by atherothrombotic disease challenge understanding of the benefits of revascularization. Aim Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) will test whether carotid endarterectomy or carotid stenting plus contemporary intensive medical therapy is superior to intensive medical therapy alone in the primary prevention of stroke in patients with high-grade asymptomatic carotid stenosis. Methods and design CREST-2 is two multicenter randomized trials of revascularization plus intensive medical therapy versus intensive medical therapy alone. One trial randomizes patients to carotid endarterectomy plus intensive medical therapy versus intensive medical therapy alone; the other, to carotid stenting plus intensive medical therapy versus intensive medical therapy alone. The risk factor targets of centrally directed intensive medical therapy are LDL cholesterol <70 mg/dl and systolic blood pressure <140 mmHg. Study outcomes The primary outcome is the composite of stroke and death within 44 days following randomization and stroke ipsilateral to the target vessel thereafter, up to four years. Change in cognition and differences in major and minor stroke are secondary outcomes. Sample size Enrollment of 1240 patients in each trial provides 85% power to detect a treatment difference if the event rate in the intensive medical therapy alone arm is 4.8% higher or 2.8% lower than an anticipated 3.6% rate in the revascularization arm. Discussion Management of asymptomatic carotid stenosis requires contemporary randomized trials to address whether carotid endarterectomy or carotid stenting plus intensive medical therapy is superior in preventing stroke beyond intensive medical therapy alone. Whether carotid endarterectomy or carotid stenting has favorable effects on cognition will also be tested. Trial registration United States National Institutes of Health Clinicaltrials.gov NCT02089217
Medicaid Savings From The New York University Caregiver Intervention for Families with Dementia
Moriarty, James P. , Farseth, Paul, Mittelman, Mary , Long, Kirsten Hall , Foldes, Steven S.

Mayo Clinic

The Gerontologist | May 2, 2017 | Volume: 58 | Issue: 2 | Pages: e97-e106

10.1093/geront/gnx077 | PMID 29106531 Get It

Polymyalgia Rheumatica
Matteson, Eric L. , Dejaco, Christian , Dejaco, Christian

Mayo Clinic

Annals of Internal Medicine | May 1, 2017 | Volume: 166 | Issue: 9 | Pages: ITC65-ITC80

10.7326/aitc201705020 | PMID 28460395 Get It